Press Releases

Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher® Barrett’s Esophagus Assay

Cernostics, pioneer of the worlds’ first precision medicine test to predict future development risk of esophageal cancer from Barrett’s esophagus (BE), TissueCypher® Barrett’s Esophagus Assay, has become a participating (“in-network”) provider for Geisinger Health Plan (GHP)’s more than 550,000 plan members in Central, North Central and East Central Pennsylvania. Read More

Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher® Barrett’s Esophagus Assay2022-05-10T16:31:37+00:00

Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE

Study further validates TissueCypher® as the first and only precision medicine test proven to provide actionable dat Read More

Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE2022-02-24T17:23:37+00:00

TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

Data presented at ACG, UEGW illustrates the 4th independent validation of TissueCypher performance for risk stratify Read More

TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences2022-02-24T17:24:26+00:00

Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019

PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) — Cernostics, developer of next-genera Read More

Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 20192022-05-10T16:37:09+00:00
Copyright © 2021 Castle Biosciences, Inc. | All Rights Reserved. Privacy
Go to Top